Rikke

KalVista Pharmaceuticals awarded UK Promising Innovative Medicine (PIM) designation for sebetralstat KalVista Pharmaceuticals today announced the UK Medicines and Healthcare products Regulatory Agency (MHRA) has awarded the Promising Innovative Medicine (PIM) designation for sebetralstat, an investigational novel, oral plasma kallikrein inhibitor for the on-demand treatment of hereditary angioedema (HAE). The PIM is the first [...]

KalVista Pharmaceuticals reports third fiscal quarter results and provides operational update KalVista Pharmaceuticals today provided an operational update and released financial results for the third fiscal quarter ended 31 January 2024. Ben Palleiko, Chief Executive Officer of KalVista, said: “This has been an exciting and busy period for KalVista, as we achieved key milestones [...]

KalVista Pharmaceuticals to present HAE attack journey data at 2024 HAEi Regional Conference Americas KalVista Pharmaceuticals today announced the acceptance of multiple abstracts at the 2024 HAEi Regional Conference meeting taking place in Panama City, Panama from 15-17 March 2024. KalVista is a Silver-level sponsor of the meeting. The presentations are: Relationship Between Time [...]

Astria Therapeutics reports fourth quarter and full year 2023 financial results and provides a corporate update Astra Therapeutics today announced today reported financial results for the fourth quarter and full year ended 31 December 2023, and provided a corporate update. Jill C Milne, Chief Executive Officer at Astria Therapeutics, said: “We have strong conviction [...]

BioCryst reports fourth quarter and full year 2023 financial results and upcoming key milestones Biocryst Pharmaceuticals Inc today reported financial results for the fourth quarter and full year ended 31 December 2023, and provided a corporate update. Jon Stonehouse, President and Chief Executive Officer of BioCryst. “The impressive growth we are seeing with Orladeyo [...]

KalVista Pharmaceuticals presents additional phase-3 KONFIDENT data at the 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting KalVista Pharmaceuticals today announced that it presented additional data on its phase 3 KONFIDENT trial for sebetralstat, including a more in-depth analysis of sebetralstat efficacy and safety at the 2024 American Academy of Allergy, Asthma [...]

KalVista Pharmaceuticals presents data on unmet needs in HAE from a Patient Perspective at the 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting KalVista Pharmaceuticals today announced that it presented real-world data from US patient surveys that assessed the experience of HAE patients using injectable on-demand treatments at the 2024 American Academy [...]

BioCryst presents new real-world data showing rapid, substantial and sustained HAE attack rate reductions after beginning Orladeyo (berotralstat) treatment Biocryst Pharmaceuticals Inc today announced new analyses of real-world use of oral, once-daily Orladeyo (berotralstat) that showed patients who initiated Orladeyo experienced rapid, substantial and sustained reductions in attack rates through 18 months of treatment [...]

Intellia Therapeutics announces fourth quarter and full-year 2023 financial results and highlights recent company progress Intellia Therapeutics today reported operational highlights and financial results for the fourth quarter and year ended December 31, 2023. Intellia President and Chief Executive Officer, John Leonard MD, said: “We’re off to a very strong start in 2024 as [...]

Positive Results from CHAPTER-1 Phase 2 Study of Deucrictibant for the Prophylactic Treatment of HAE Attacks to be Presented at AAAAI 2024 Annual Meeting Pharvaris today announced the upcoming presentation of two posters at the American Academy of Allergy, Asthma, & Immunology (AAAAI) 2024 Annual Scientific Meeting, to be held in Washington DC from [...]